Investment Thesis
Pulmatrix is a pre-commercial pharmaceutical company with $53K in revenue against $1.2M in net losses, exhibiting unsustainable cash burn of $1.1M annually against a $3.3M cash reserve (~3-year runway). The company faces binary clinical/development risk with no near-term profitability path and will likely require dilutive capital raises to fund operations.
Strengths
- Clean balance sheet with zero long-term debt
- Strong liquidity position (4.96x current ratio) providing operational buffer
- Revenue growth of 1571.5% YoY and net loss improvement of 46% YoY suggest positive traction
Risks
- Unsustainable cash burn rate ($1.1M annually) relative to $53K revenue base and limited runway
- Pre-commercial pharmaceutical company with binary clinical development outcomes and regulatory risks
- Will require dilutive capital raises to continue operations; zero insider buying activity suggests limited confidence
- Operating margin of -2438% indicates business model not yet viable at scale
Key Metrics to Watch
- Quarterly cash burn trends and cash runway depletion rate
- Clinical trial progress milestones and regulatory developments
- Path to revenue scaling and timeline to positive operating cash flow
Financial Metrics
Revenue
53.0K
Net Income
-1.2M
EPS (Diluted)
$-0.32
Free Cash Flow
-1.5M
Total Assets
4.5M
Cash
3.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,437.7%
Net Margin
-2,211.3%
ROE
-32.6%
ROA
-26.1%
FCF Margin
-2,764.2%
Balance Sheet & Liquidity
Current Ratio
4.96x
Quick Ratio
4.96x
Debt/Equity
0.00x
Debt/Assets
20.1%
Interest Coverage
-6.95x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:06:43.689869 |
Data as of: 2026-03-31 |
Powered by Claude AI